Literature DB >> 9292710

Immunocytochemical detection of P-glycoprotein in the management of malignant effusions.

P Athanassiadou1, P Athanassiades, E Petrakakou, C Zerva, M Mavrikakis.   

Abstract

P-glycoprotein (P-gp), a cell membrane protein, has been found in multidrug-resistant cancer cells. A total of 104 smears from patients with breast-cancer-associated pleural effusions and ovarian-cancer-related peritoneal effusions were studied for P-gp with the antibody C-219 and the avidin-biotin-immunoperoxidase method. Samples were taken before and 3 and 7 days after intracavitary bleomycin therapy and reaccumulation of effusion was assessed at 30 days. Smears that were P-gp-negative by the 7th day were associated with a good 30-day response to bleomycin in the majority of cases, while P-gp-positive smears were associated with a significant reaccumulation of fluid at 30 days. P-gp status is a valuable prognostic indicator of response to intracavitary bleomycin treatment in effusions from breast or ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9292710     DOI: 10.1007/BF01372551

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  21 in total

1.  P-glycoprotein expression in non-hodgkins-lymphoma.

Authors:  R West; E Boyle; D Grignon; I Chinyee
Journal:  Int J Oncol       Date:  1994-06       Impact factor: 5.650

Review 2.  Multiple-drug resistance in human cancer.

Authors:  I Pastan; M Gottesman
Journal:  N Engl J Med       Date:  1987-05-28       Impact factor: 91.245

3.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

Review 4.  Multidrug resistance in cancer.

Authors:  N Kartner; V Ling
Journal:  Sci Am       Date:  1989-03       Impact factor: 2.142

5.  Intracavitary bleomycin in the management of malignant effusions: a multicenter study.

Authors:  M J Ostrowski; G M Halsall
Journal:  Cancer Treat Rep       Date:  1982-11

6.  Intracavitary bleomycin in the management of malignant effusions.

Authors:  W Paladine; T J Cunningham; R Sponzo; M Donavan; K Olson; J Horton
Journal:  Cancer       Date:  1976-11       Impact factor: 6.860

7.  Monoclonal antibody C219 detection of the multidrug-resistant protein P-glycoprotein in routinely processed tissues: a study of 36 cases of ovarian carcinoma.

Authors:  M L Rutledge; S S Robey-Cafferty; E G Silva; J M Bruner
Journal:  Mod Pathol       Date:  1990-05       Impact factor: 7.842

8.  Reversal of multidrug resistance by verapamil and modulation by alpha 1-acid glycoprotein in wild-type and multidrug-resistant Chinese hamster ovary cell lines.

Authors:  M Chatterjee; C N Robson; A L Harris
Journal:  Cancer Res       Date:  1990-05-01       Impact factor: 12.701

9.  Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer.

Authors:  J Ro; A Sahin; J Y Ro; H Fritsche; G Hortobagyi; M Blick
Journal:  Hum Pathol       Date:  1990-08       Impact factor: 3.466

10.  Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines.

Authors:  H Takeshita; M C Gebhardt; D S Springfield; K Kusuzaki; H J Mankin
Journal:  J Bone Joint Surg Am       Date:  1996-03       Impact factor: 5.284

View more
  1 in total

1.  The Impact of Melatonin on Colon Cancer Cells' Resistance to Doxorubicin in an in Vitro Study.

Authors:  Magdalena Fic; Agnieszka Gomulkiewicz; Jedrzej Grzegrzolka; Marzenna Podhorska-Okolow; Maciej Zabel; Piotr Dziegiel; Karolina Jablonska
Journal:  Int J Mol Sci       Date:  2017-06-29       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.